New combo therapy aims to wake up immune system against stubborn cancers
NCT ID NCT05338658
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This early-phase study tests a new approach called peptide alarm therapy (PAT) given as an injection directly into tumors, along with a standard immunotherapy drug, for people with advanced solid tumors that have stopped responding to at least one prior treatment. The goal is to find the safest dose and see if the combination can help control the cancer. About 21 adults who have had certain past infections (CMV and EBV) and a specific genetic marker (HLA-A*0201) are eligible to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Masonic Cancer Center at University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact
Conditions
Explore the condition pages connected to this study.